RU2006131997A - Алкалоидные составы - Google Patents
Алкалоидные составы Download PDFInfo
- Publication number
- RU2006131997A RU2006131997A RU2006131997/15A RU2006131997A RU2006131997A RU 2006131997 A RU2006131997 A RU 2006131997A RU 2006131997/15 A RU2006131997/15 A RU 2006131997/15A RU 2006131997 A RU2006131997 A RU 2006131997A RU 2006131997 A RU2006131997 A RU 2006131997A
- Authority
- RU
- Russia
- Prior art keywords
- alkaloid
- composition according
- electron transfer
- alkaloid composition
- phosphate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 44
- 229930013930 alkaloid Natural products 0.000 title claims abstract 39
- 150000003797 alkaloid derivatives Chemical class 0.000 title claims abstract 34
- 239000012992 electron transfer agent Substances 0.000 claims abstract 22
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims abstract 16
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract 8
- 239000010452 phosphate Substances 0.000 claims abstract 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract 8
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical class OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 claims abstract 5
- 239000007795 chemical reaction product Substances 0.000 claims abstract 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract 4
- -1 alpha Chemical class 0.000 claims abstract 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000011772 phylloquinone Substances 0.000 claims abstract 4
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims abstract 4
- 235000019175 phylloquinone Nutrition 0.000 claims abstract 4
- 229960001898 phytomenadione Drugs 0.000 claims abstract 4
- 239000011607 retinol Substances 0.000 claims abstract 4
- 229960003471 retinol Drugs 0.000 claims abstract 4
- 235000020944 retinol Nutrition 0.000 claims abstract 4
- 235000010384 tocopherol Nutrition 0.000 claims abstract 4
- 229930003799 tocopherol Natural products 0.000 claims abstract 4
- 239000011732 tocopherol Substances 0.000 claims abstract 4
- 229960001295 tocopherol Drugs 0.000 claims abstract 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract 4
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 claims abstract 2
- FVOOPOSZDXPIMS-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-2-ol Chemical class C1=CC=C2OC(O)CCC2=C1 FVOOPOSZDXPIMS-UHFFFAOYSA-N 0.000 claims abstract 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 claims abstract 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940087168 alpha tocopherol Drugs 0.000 claims abstract 2
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract 2
- 239000011668 ascorbic acid Substances 0.000 claims abstract 2
- 229960005070 ascorbic acid Drugs 0.000 claims abstract 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract 2
- 229960002061 ergocalciferol Drugs 0.000 claims abstract 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960000984 tocofersolan Drugs 0.000 claims abstract 2
- 229940035936 ubiquinone Drugs 0.000 claims abstract 2
- 235000001892 vitamin D2 Nutrition 0.000 claims abstract 2
- 239000011653 vitamin D2 Substances 0.000 claims abstract 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims abstract 2
- 235000004835 α-tocopherol Nutrition 0.000 claims abstract 2
- 239000002076 α-tocopherol Substances 0.000 claims abstract 2
- 125000001020 α-tocopherol group Chemical group 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 229930003347 Atropine Natural products 0.000 claims 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims 2
- 229960000396 atropine Drugs 0.000 claims 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 230000035764 nutrition Effects 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- FVNFBBAOMBJTST-UHFFFAOYSA-N 8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound O1C(=O)NCC11CCN(CCC=2C=CC=CC=2)CC1 FVNFBBAOMBJTST-UHFFFAOYSA-N 0.000 claims 1
- 235000001258 Cinchona calisaya Nutrition 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 235000008452 baby food Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000007910 chewable tablet Substances 0.000 claims 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 229960002912 fenspiride Drugs 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229960000948 quinine Drugs 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 150000003512 tertiary amines Chemical class 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Алкалоидный состав, содержащий продукт реакции одного или более алкалоидов с одним или более фосфатных производных одного или более агентов электронного переноса.2. Алкалоидный состав по п.1, в котором агент электронного переноса выбран из группы, содержащей гидроксихроманы, в том числе альфа-, бета, гамма- и дельта-токолы в энантиомерной и рацемической формах; хинолы, которые являются восстановленными формами витамина К1 и убихинона; гидроксикаратиноиды, в том числе ретинол; кальциферол, аскорбинововую кислоту и их смеси.3. Алкалоидный состав по п.1, в котором агент электронного переноса выбран из группы, состоящей из токоферола и других токолов, ретинола, витамина К1 и их смесей.4. Алкалоидный состав по п.1, в котором агент электронного переноса выбран из группы, состоящей из токолов и их смесей.5. Алкалоидный состав по п.1, в котором агент электронного переноса представляет собой α-токоферол.6. Алкалоидный состав по п.1, в котором одно или более фосфатных производных одного или более агента электронного переноса выбрано из группы, содержащей одно или более фосфатных производных токоферола.7. Алкалоидный состав по п.1, в котором одно или более фосфатных производных одного и более агентов электронного переноса выбрано из группы, состоящей из монотокоферилфосфата, дитокоферилфосфата и их смесей.8. Алкалоидный состав по п.1, в котором одно или более фосфатных производных одного и более агентов электронного переноса представляет собой смесь монотокоферилфосфата и дитокоферилфосфата.9. Алкалоидный состав по п.1, в котором одно или более фосфатных производных одного и более агентов электронного переноса представляет �
Claims (20)
1. Алкалоидный состав, содержащий продукт реакции одного или более алкалоидов с одним или более фосфатных производных одного или более агентов электронного переноса.
2. Алкалоидный состав по п.1, в котором агент электронного переноса выбран из группы, содержащей гидроксихроманы, в том числе альфа-, бета, гамма- и дельта-токолы в энантиомерной и рацемической формах; хинолы, которые являются восстановленными формами витамина К1 и убихинона; гидроксикаратиноиды, в том числе ретинол; кальциферол, аскорбинововую кислоту и их смеси.
3. Алкалоидный состав по п.1, в котором агент электронного переноса выбран из группы, состоящей из токоферола и других токолов, ретинола, витамина К1 и их смесей.
4. Алкалоидный состав по п.1, в котором агент электронного переноса выбран из группы, состоящей из токолов и их смесей.
5. Алкалоидный состав по п.1, в котором агент электронного переноса представляет собой α-токоферол.
6. Алкалоидный состав по п.1, в котором одно или более фосфатных производных одного или более агента электронного переноса выбрано из группы, содержащей одно или более фосфатных производных токоферола.
7. Алкалоидный состав по п.1, в котором одно или более фосфатных производных одного и более агентов электронного переноса выбрано из группы, состоящей из монотокоферилфосфата, дитокоферилфосфата и их смесей.
8. Алкалоидный состав по п.1, в котором одно или более фосфатных производных одного и более агентов электронного переноса представляет собой смесь монотокоферилфосфата и дитокоферилфосфата.
9. Алкалоидный состав по п.1, в котором одно или более фосфатных производных одного и более агентов электронного переноса представляет собой фосфатид.
10. Алкалоидный состав по п.1, в котором алкалоид выбран из группы, состоящей из третичных аминов, которые являются алициклическими и имеют атом азота, общий для трех колец; являются циклическими, где атом азота включен в одно кольцо и алкилирован; или не имеют циклической структуры, включающей азот; а также их смесей.
11. Алкалоидный состав по п.10, в котором алкалоид выбран из группы, состоящей из атропина, хинина, опиоидов, фентанила, никотина, фенспирида, флюразепана и кодеина.
12. Алкалоидный состав по п.11, в котором алкалоид представляет собой атропин или морфин.
13. Алкалоидный состав по п.1, представляющий собой состав для местного применения, для перорального введения, или трансбуккального введения.
14. Алкалоидный состав по п.13, представляющий собой состав для перорального введения дополнительно содержит энтеральное покрытие.
15. Алкалоидный состав по п.13, представляющий собой состав, выбранный из группы, состоящей из таблеток, жевательных таблеток, капсул, порошков, суспензий, оральных суспензий, эмульсий, жидкостей, детского питания, энтерального питания, нутрацевтиков и функционального питания, пищевых добавок, суппозиториев, пластыря, крема или геля.
16. Алкалоидный состав по п.1, представляющий собой состав, предназначенный для парентерального введения, назального введения, дермального или трансдермального введения.
17. Способ повышения эффективности алкалоида, включающий реагирование алкалоида с одним или более фосфатных производных одного или более агентов электронного переноса.
18. Применение продукта реакции одного или более алкалоидов с одним или более фосфатных производных одного или более агентов электронного переноса для изготовления алкалоидного состава.
19. Применение алкалоидного состава, содержащего продукт реакции одного или более алкалоидов с одним или более фосфатных производных одного или более агентов электронного переноса для производства лекарственного препарата, имеющего повышенную эффективность.
20. Фармацевтическая композиция, содержащая алкалоидный состав, включающий продукт реакции одного или более алкалоидов с одним или более фосфатных производных одного или более агентов электронного переноса и фармацевтически приемлемую добавку.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004901107A AU2004901107A0 (en) | 2004-03-03 | Alkaloid formulation | |
| AU2004901107 | 2004-03-03 | ||
| AU2004904367 | 2004-08-03 | ||
| AU2004904367A AU2004904367A0 (en) | 2004-08-03 | Alkaloid formulations | |
| PCT/AU2005/000307 WO2005084678A1 (en) | 2004-03-03 | 2005-03-03 | Alkaloid formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006131997A true RU2006131997A (ru) | 2008-04-10 |
| RU2477136C2 RU2477136C2 (ru) | 2013-03-10 |
Family
ID=34921028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006131997/15A RU2477136C2 (ru) | 2004-03-03 | 2005-03-03 | Алкалоидные составы |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20060281716A1 (ru) |
| EP (1) | EP1720551B9 (ru) |
| JP (1) | JP4847437B2 (ru) |
| KR (1) | KR101173159B1 (ru) |
| AT (1) | ATE495730T1 (ru) |
| AU (1) | AU2005202477B2 (ru) |
| BR (1) | BRPI0508125A (ru) |
| CA (1) | CA2557354C (ru) |
| DE (1) | DE602005025979D1 (ru) |
| DK (1) | DK1720551T3 (ru) |
| IL (1) | IL177781A (ru) |
| NZ (1) | NZ549567A (ru) |
| RU (1) | RU2477136C2 (ru) |
| WO (1) | WO2005084678A1 (ru) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1482102A (en) * | 2000-11-14 | 2002-05-27 | Tocovite Pty Ltd | Complexes of phosphate derivatives |
| AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
| CA2453823C (en) * | 2001-07-27 | 2010-12-21 | Vital Health Sciences Pty Ltd | Dermal therapy using phosphate derivatives of electron transfer agents |
| EP1460995B1 (en) * | 2001-12-13 | 2010-11-10 | Vital Health Sciences Pty Ltd. | Transdermal transport of compounds |
| AU2002950713A0 (en) * | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| BRPI0406484A (pt) * | 2003-01-17 | 2005-12-06 | Vital Health Sciences Pty Ltd | Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado |
| AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
| AU2005202477B2 (en) | 2004-03-03 | 2005-12-15 | Vital Health Sciences Pty Ltd | Alkaloid formulations |
| MX2007001356A (es) * | 2004-08-03 | 2007-04-23 | Vital Health Sciences Pty Ltd | Portador para administracion enterica. |
| US20090239827A1 (en) * | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
| EP1858508A4 (en) * | 2005-03-03 | 2009-01-07 | Vital Health Sciences Pty Ltd | COMPOUNDS HAVING ANTICANCER PROPERTIES |
| CA2611831C (en) * | 2005-06-17 | 2014-09-16 | Vital Health Sciences Pty Ltd. | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| US20090005348A1 (en) * | 2005-12-23 | 2009-01-01 | Vital Health Sciences Pty Ltd | Compounds Having Cytokine Modulating Properties |
| WO2011094814A1 (en) | 2010-02-05 | 2011-08-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| AU2011235597B2 (en) | 2010-03-30 | 2015-07-16 | Phosphagenics Limited | Transdermal delivery patch |
| WO2012122586A1 (en) | 2011-03-15 | 2012-09-20 | Phosphagenics Limited | New composition |
| US10402738B2 (en) | 2012-12-03 | 2019-09-03 | National Ict Australia Limited | Bayesian nonparametric method for infrastructure failure prediction |
| TWI685497B (zh) * | 2014-06-02 | 2020-02-21 | 西班牙商伊史帝夫製藥公司 | 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物 |
| AR106697A1 (es) | 2015-11-16 | 2018-02-07 | Esteve Labor Dr | Compuestos oxadiazoespíricos para el tratamiento del abuso y la adicción a las drogas |
| US10973761B2 (en) | 2015-12-09 | 2021-04-13 | Phosphagenics Limited | Pharmaceutical formulation |
| RU2742650C2 (ru) * | 2015-12-09 | 2021-02-09 | Фосфейдженикс Лимитед | Фармацевтический состав |
| MX392823B (es) | 2016-12-21 | 2025-03-24 | Avecho Biotechnology Ltd | Proceso de fosforilaciónde un alcohol complejo |
| US20230381207A1 (en) | 2020-10-19 | 2023-11-30 | Avecho Biotechnology Limited | Oral cannabinoid formulation comprising tocopheryl phosphates and long chain triglycerides or long chain fatty acids |
| US20230381208A1 (en) | 2020-10-19 | 2023-11-30 | Avecho Biotechnology Limited | Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates |
| WO2022155656A1 (en) | 2021-01-13 | 2022-07-21 | Rodan & Fields, Llc | Cosmetic compositions |
Family Cites Families (182)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2407823A (en) * | 1946-09-17 | Antihemorrhagic esters and methods | ||
| US2667479A (en) * | 1951-01-30 | 1954-01-26 | Merck & Co Inc | Benzimidazole phosphate |
| GB778142A (en) | 1953-11-20 | 1957-07-03 | Leo Ab | High-molecular weight derivatives of hydroxyl group-containing steroids and a method of producing them |
| US2913477A (en) * | 1957-03-22 | 1959-11-17 | Merck & Co Inc | Antihemorrhagic compounds and processes for preparing the same |
| US3127434A (en) * | 1959-10-20 | 1964-03-31 | Hoffmann La Roche | Dihydrovitamin k monophosphate compounds and preparation thereof |
| US3212901A (en) * | 1961-06-07 | 1965-10-19 | Eastman Kodak Co | Stabilized tocopherol concentrates and process for preparing the same |
| US3331896A (en) | 1964-09-15 | 1967-07-18 | Gen Aniline & Film Corp | Method of preparing alkali soluble phosphate esters of hydroxylic organic compounds |
| US3607765A (en) * | 1968-11-29 | 1971-09-21 | Colgate Polmolive Co | Detergent softener compositions |
| DE2526938C2 (de) * | 1975-02-14 | 1982-04-22 | F. Hoffmann-La Roche & Co. AG, 4002 Basel | Vitaminpräparate |
| US4141938A (en) * | 1976-10-07 | 1979-02-27 | Hoechst Aktiengesellschaft | Production of acid orthophosphoric acid ester mixtures |
| US4444755A (en) * | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
| US4299906A (en) * | 1979-06-01 | 1981-11-10 | American Hoechst Corporation | Light-sensitive color proofing film with surfactant in a light-sensitive coating |
| SU925961A1 (ru) | 1980-08-15 | 1982-05-07 | Московский ордена Трудового Красного Знамени технологический институт пищевой промышленности | Способ получени фосфорилированных глицеридов высших жирных кислот |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| IT1157269B (it) * | 1982-03-19 | 1987-02-11 | Seuref Ag | Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica |
| CH661438A5 (it) * | 1984-04-09 | 1987-07-31 | Seuref Ag | Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale. |
| US4977282A (en) * | 1984-04-17 | 1990-12-11 | Henkel Corporation | Production of d-alpha-tocopherol from natural plant sources |
| US4603142A (en) * | 1984-06-01 | 1986-07-29 | Wisconsin Alumni Research Foundation | Cholesterol lowering method of use |
| DE3582904D1 (de) | 1984-08-02 | 1991-06-27 | Henkel Corp | Reinigung von tocopherolen durch extraktion. |
| JPS6191137A (ja) * | 1984-10-11 | 1986-05-09 | Kao Corp | 外用薬剤組成物 |
| JPH0781138B2 (ja) | 1986-12-02 | 1995-08-30 | 株式会社資生堂 | 抗酸化剤 |
| DE3702766A1 (de) * | 1987-01-30 | 1988-08-11 | Henkel Kgaa | Verfahren zur herstellung und isolierung von monoalkylphosphorsaeureestern |
| JP3070744B2 (ja) * | 1987-04-10 | 2000-07-31 | 株式会社日立製作所 | ベクトル処理装置 |
| US4952495A (en) * | 1987-06-08 | 1990-08-28 | Eastman Kodak Company | Hydrolyzable compounds which release electron transfer agents and analytical use of same |
| PH25859A (en) | 1988-01-11 | 1991-12-02 | Takeda Chemical Industries Ltd | Composition for treatment of ischemic disorder |
| US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| DE3813624A1 (de) | 1988-04-22 | 1989-11-02 | Basf Ag | Verfahren zur herstellung von d-(alpha)-tocopherol aus natuerlichen vorprodukten |
| CA2007643A1 (en) | 1989-02-01 | 1990-08-01 | Donald S. Karanewsky | Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination |
| US6028105A (en) * | 1989-04-06 | 2000-02-22 | Nigra; Thomas P. | Topical drug delivery composition and method |
| US5053222A (en) * | 1989-06-07 | 1991-10-01 | Shiseido Company Ltd. | Hair cosmetic composition |
| US5094848A (en) | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
| DE3927113C2 (de) * | 1989-08-17 | 1993-11-25 | Dolorgiet Gmbh & Co Kg | Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung |
| JP2854631B2 (ja) | 1989-11-21 | 1999-02-03 | 千寿製薬株式会社 | 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤 |
| IT1236843B (it) * | 1989-11-22 | 1993-04-21 | Simes | Processo per la preparazione di 4-0-fosfati di dopamina o suoi derivati |
| JPH03206089A (ja) | 1990-01-05 | 1991-09-09 | Eisai Co Ltd | 新規ビタミンｅ誘導体及びその製造方法 |
| US5374645A (en) * | 1990-01-22 | 1994-12-20 | Ciba-Geigy Corporation | Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol |
| FR2657526B1 (fr) * | 1990-01-31 | 1994-10-28 | Lvmh Rech | Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues. |
| US5041434A (en) * | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| US5114957A (en) | 1990-05-08 | 1992-05-19 | Biodor U.S. Holding | Tocopherol-based antiviral agents and method of using same |
| US5591772A (en) * | 1991-11-22 | 1997-01-07 | Lipogenics, Inc. | Tocotrienols and tocotrienol-like compounds and methods for their use |
| SE9003665D0 (sv) * | 1990-11-16 | 1990-11-16 | Kabivitrum Ab | Morphine prodrugs |
| FR2679904A1 (fr) * | 1991-08-01 | 1993-02-05 | Lvmh Rech | Utilisation d'un phosphate de tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, ou pharmaceutiques et compositions ainsi obtenues. |
| US5643597A (en) * | 1991-08-01 | 1997-07-01 | Lvmh Recherche | Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained |
| EP0535283A1 (en) | 1991-10-02 | 1993-04-07 | Merrell Dow Pharmaceuticals Inc. | Cardioprotective tocopherol analogs |
| US5474891A (en) * | 1991-10-30 | 1995-12-12 | Thomas Jefferson University | Plasma-based platelet concentrate preparations with additive |
| DK0612521T3 (da) | 1991-11-11 | 2000-01-17 | Hisamitsu Pharmaceutical Co | Keterolacholdigt varmt omslag |
| US5282312A (en) * | 1991-12-31 | 1994-02-01 | Tessera, Inc. | Multi-layer circuit construction methods with customization features |
| JP3202775B2 (ja) * | 1992-01-29 | 2001-08-27 | エスエス製薬株式会社 | 固形製剤 |
| JP3207494B2 (ja) * | 1992-04-02 | 2001-09-10 | ロート製薬株式会社 | 水性懸濁製剤 |
| JPH05286848A (ja) | 1992-04-10 | 1993-11-02 | Senju Pharmaceut Co Ltd | 浴用剤 |
| GB9212450D0 (en) | 1992-06-11 | 1992-07-22 | Indena Spa | New derivatives of non-steroidal anti-inflammatory,analgesic and/or antipyretic substances,their use and pharmaceutical formulations containing them |
| US5741518A (en) * | 1992-08-03 | 1998-04-21 | L'oreal | Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids |
| US5773457A (en) * | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
| WO1994008599A1 (en) * | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
| US5348357A (en) | 1992-12-24 | 1994-09-20 | General Motors Corporation | Vehicle closure latch having plastic coated ratchet |
| US6384043B1 (en) * | 1993-02-01 | 2002-05-07 | Gholam A. Peyman | Methods of alleviating pain sensations of the denuded eye with opioid analgesics |
| TW252918B (ru) | 1993-03-31 | 1995-08-01 | Senju Pharma Co | |
| GB9318271D0 (en) | 1993-09-03 | 1993-10-20 | Scotia Holdings Plc | Tocopherols |
| CA2129509A1 (en) | 1993-09-10 | 1995-03-11 | Kazumi Ogata | Pharmaceutical composition for renal disorder and a dialysis solution for extracorporeal hemodialysis |
| US5807542A (en) * | 1993-11-27 | 1998-09-15 | Knoll Aktiengesellschaft | Chemical compositions for inhibiting nitrosation reaction in toiletries and cosmetics |
| JPH07196516A (ja) | 1993-12-29 | 1995-08-01 | Senju Pharmaceut Co Ltd | 痔疾患治療剤 |
| FR2714595B1 (fr) * | 1993-12-30 | 1996-02-02 | Oreal | Emulsion eau dans huile contenant du rétinol, son utilisation et son conditionnement. |
| FR2715565B1 (fr) * | 1994-01-31 | 1996-03-15 | Oreal | Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation. |
| US5444957A (en) * | 1994-02-01 | 1995-08-29 | Roberts; Walter R. | Multistory slab construction |
| EP0669132A1 (en) | 1994-02-23 | 1995-08-30 | van der Kraaij, Antonius Marinus Maria | Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis |
| CA2145229A1 (en) | 1994-03-29 | 1995-09-30 | Tetsuya Toge | Suppressory compositions against hepatic metastases of tumors |
| US5554781A (en) * | 1994-03-30 | 1996-09-10 | Reierson; Robert L. | Monoalkyl phosphonic acid ester production process |
| JPH07277988A (ja) | 1994-04-05 | 1995-10-24 | Senju Pharmaceut Co Ltd | 局所用掻痒除去、治療剤 |
| TW287103B (ru) | 1994-04-22 | 1996-10-01 | Senju Pharma Co | |
| JP3362501B2 (ja) | 1994-04-28 | 2003-01-07 | 千寿製薬株式会社 | 角膜障害治療剤 |
| JP3396953B2 (ja) | 1994-05-10 | 2003-04-14 | 千寿製薬株式会社 | 網膜疾患予防・治療剤 |
| US5589504A (en) * | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
| CA2152693A1 (en) | 1994-08-05 | 1996-02-06 | Kazumi Ogata | Therapeutic composition for pancreatitis |
| IT1274734B (it) | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
| JPH0873338A (ja) * | 1994-09-02 | 1996-03-19 | Noevir Co Ltd | 皮膚外用剤 |
| HU215966B (hu) * | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum |
| DE4444238A1 (de) * | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden |
| FR2730928B1 (fr) * | 1995-02-23 | 1997-04-04 | Oreal | Composition a base de vesicules lipidiques a ph acide et son utilisation en application topique |
| CA2193742A1 (en) * | 1995-04-21 | 1996-10-24 | Tatsuo Shimizu | External preparations for treating dermatoses |
| US5607968A (en) * | 1995-06-07 | 1997-03-04 | Avon Products, Inc. | Topical alkyl-2-O-L-ascorbyl-phosphates |
| CN1069320C (zh) * | 1995-10-17 | 2001-08-08 | 昭和电工株式会社 | 高纯度生育酚磷酸酯,其生产方法和含有该化合物的化妆品 |
| FR2741263B1 (fr) | 1995-11-22 | 1997-12-26 | Oreal | Composition comprenant une dispersion aqueuse de vesicules lipidiques encapsulant un filtre uv a fonction acide et utilisations en application topique |
| WO1997035591A2 (en) | 1996-03-27 | 1997-10-02 | Inspire Pharmaceuticals, Inc. | Method of treating ciliary dyskinesia with uridine triphosphates and related compounds |
| US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| US5885595A (en) * | 1996-05-13 | 1999-03-23 | Elizabeth Arden Co., Division Of Conopco, Inc. | Cosmetic composition with a retinol fatty acid ester |
| CA2209690A1 (en) * | 1996-07-31 | 1998-01-31 | Sachiko Matsuura | Therapeutic drug for acne vulgaris |
| JPH1067639A (ja) | 1996-08-26 | 1998-03-10 | Shiseido Co Ltd | ビタミンｅ−ビタミンｃリン酸ジエステル／シクロデキストリン包接物及び該包接物を配合した皮膚外用剤 |
| JPH10155429A (ja) | 1996-11-27 | 1998-06-16 | Showa Denko Kk | 動物に対するビタミンｅ供給方法および動物用トコフェロールリン酸エステル又はその塩類組成物 |
| US6022867A (en) * | 1996-11-27 | 2000-02-08 | Showa Denko Kabushiki Kaisha | Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals |
| US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US6727280B2 (en) * | 1997-01-07 | 2004-04-27 | Sonus Pharmaceuticals, Inc. | Method for treating colorectal carcinoma using a taxane/tocopherol formulation |
| US6932975B2 (en) | 1997-01-29 | 2005-08-23 | Kao Corporation | Cosmetic composition comprising a phosphoric triester and a skin activating component |
| US5804168A (en) * | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
| US6248758B1 (en) * | 1997-03-13 | 2001-06-19 | Hexal Ag | Pharmaceutical antacid |
| US7179486B1 (en) * | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
| JP2926046B2 (ja) * | 1997-06-04 | 1999-07-28 | 株式会社太平洋 | 水安定型ｌ−アスコルビン酸誘導体とその製造方法及びこれを含有する美白化粧料組成物 |
| US5928631A (en) * | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
| US5906811A (en) * | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
| US5776915A (en) | 1997-08-12 | 1998-07-07 | Clarion Pharmaceuticals Inc. | Phosphocholines of retinoids |
| US6096326A (en) * | 1997-08-15 | 2000-08-01 | Scandinavian-American Import/Export Corporation | Skin care compositions and use |
| IT1294748B1 (it) * | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | Formulazione per un dispositivo transdermico |
| CA2317008C (en) * | 1997-12-31 | 2009-01-20 | The University Of Kansas | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
| CA2319020A1 (en) | 1998-02-03 | 1999-08-12 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical compositions for prevention and treatment of neurodegenarative diseases |
| FR2777179A1 (fr) | 1998-04-09 | 1999-10-15 | Lvmh Rech | Compositions cosmetiques ou dermatologiques comprenant un vehicule a base d'un liquide hydrophobe |
| US6461623B2 (en) * | 1998-04-13 | 2002-10-08 | Kao Corporation | Cosmetic composition |
| JP4208209B2 (ja) | 1998-06-22 | 2009-01-14 | フジノン株式会社 | コリメータレンズおよびこれを用いた光走査装置 |
| US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
| WO2000001351A1 (en) * | 1998-07-07 | 2000-01-13 | Transdermal Technologies, Inc. | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
| CN1318413C (zh) * | 1998-09-23 | 2007-05-30 | 研究发展基金会 | 生育酚、生育三烯酚、其它苯并二氢吡喃和侧链衍生物,及其用途 |
| US6703384B2 (en) * | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| US6770672B1 (en) * | 1998-09-23 | 2004-08-03 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| US6153582A (en) | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
| US6048891A (en) * | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
| AUPQ037499A0 (en) * | 1999-05-14 | 1999-06-10 | Swig Pty Ltd | Improved process for phosphorylation and compounds produced by this method |
| AUPP829399A0 (en) * | 1999-01-25 | 1999-02-18 | Swig Pty Ltd | Recovery for chroman derivatives |
| JP2000212082A (ja) | 1999-01-26 | 2000-08-02 | Showa Denko Kk | 皮膚用剤 |
| US6156354A (en) * | 1999-01-29 | 2000-12-05 | Brandeis University | Hyper-absorption of vitamin E dispersed in milks |
| US6184247B1 (en) * | 1999-05-21 | 2001-02-06 | Amway Corporation | Method of increasing cell renewal rate |
| AU5594700A (en) * | 1999-06-01 | 2000-12-18 | Ocean Spray Cranberries, Inc. | Cranberry seed oil extract and compositions containing components thereof |
| US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| US6423742B1 (en) * | 1999-09-02 | 2002-07-23 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
| JP2003513019A (ja) * | 1999-09-27 | 2003-04-08 | ソーナス ファーマシューティカルス，インコーポレイテッド | トコール可溶性治療剤の組成物 |
| JP2001169731A (ja) | 1999-12-17 | 2001-06-26 | Showa Denko Kk | 動物体の脂質代謝改善剤 |
| WO2001058889A1 (en) * | 2000-02-11 | 2001-08-16 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| US20030035812A1 (en) * | 2000-02-29 | 2003-02-20 | Shinobu Ito | Immune enhancement compositions and use thereof |
| US6346544B2 (en) * | 2000-03-02 | 2002-02-12 | Oklahoma Medical Research Foundation | Desmethyl tocopherols for protecting cardiovascular tissue |
| JP2001247585A (ja) | 2000-03-03 | 2001-09-11 | Nof Corp | トコフェロール誘導体、その中間体、その製造方法及び用途 |
| US6444220B2 (en) * | 2000-03-16 | 2002-09-03 | Teresa S. Wiley | Method and compositions for changing the contour of skin |
| US6361800B1 (en) * | 2000-04-13 | 2002-03-26 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
| US6485950B1 (en) * | 2000-07-14 | 2002-11-26 | Council Of Scientific And Industrial Research | Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions |
| KR100365070B1 (ko) | 2000-08-29 | 2002-12-16 | 주식회사 태평양 | 토코페롤 유도체 및 그의 제조방법 |
| JP4818500B2 (ja) | 2000-09-05 | 2011-11-16 | 株式会社ペンタプラストア | トコトリエノール誘導体及びその製造方法 |
| US20030206972A1 (en) * | 2000-10-13 | 2003-11-06 | Babish John G. | Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect |
| AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
| AU1482102A (en) * | 2000-11-14 | 2002-05-27 | Tocovite Pty Ltd | Complexes of phosphate derivatives |
| JP4620326B2 (ja) | 2000-11-14 | 2011-01-26 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | 電子移動剤のホスフェート誘導体を含有する処方 |
| US20020132845A1 (en) * | 2000-12-15 | 2002-09-19 | Miller Guy Michael | Compositions and methods for the prevention and treatment of tissue ischemia |
| US20020151467A1 (en) * | 2000-12-21 | 2002-10-17 | Leung Frank K. | Methods and compositions for oral insulin delivery |
| US20020131994A1 (en) * | 2001-01-10 | 2002-09-19 | Schur Henry B. | Non-irritating formulation for the transdermal delivery of substances |
| US6849271B2 (en) * | 2001-04-27 | 2005-02-01 | Verion, Inc. | Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods |
| TW576859B (en) * | 2001-05-11 | 2004-02-21 | Shipley Co Llc | Antireflective coating compositions |
| KR100394770B1 (ko) | 2001-06-05 | 2003-08-14 | 주식회사 태평양 | 토코페롤 유도체를 이용하여 나노유화입자를 안정화시키는방법 및 나노유화입자를 함유하는 피부 외용제 조성물 |
| CA2453823C (en) * | 2001-07-27 | 2010-12-21 | Vital Health Sciences Pty Ltd | Dermal therapy using phosphate derivatives of electron transfer agents |
| AUPR684801A0 (en) * | 2001-08-06 | 2001-08-30 | Vital Health Sciences Pty Ltd | Supplement therapy |
| WO2003024429A1 (en) * | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
| US20040253310A1 (en) * | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| MXPA04001779A (es) * | 2001-09-26 | 2004-05-31 | Vital Health Sciences Pty Ltd | Modulacion de almacenamiento de vitamina. |
| AU2002951045A0 (en) * | 2002-08-27 | 2002-09-12 | Vital Health Sciences Pty Ltd | Method of supplementing nascent endogenous storage forms |
| JP4370451B2 (ja) | 2001-09-28 | 2009-11-25 | 大塚製薬株式会社 | 医薬組成物 |
| JP2003128531A (ja) | 2001-10-17 | 2003-05-08 | Nonogawa Shoji Kk | 皮膚外用剤 |
| EP1460995B1 (en) * | 2001-12-13 | 2010-11-10 | Vital Health Sciences Pty Ltd. | Transdermal transport of compounds |
| WO2003063860A1 (en) | 2002-01-31 | 2003-08-07 | Kansai Technology Licensing Organization Co., Ltd. | Compositions for preventing human cancer and method of preventing human cancer |
| US20030220301A1 (en) * | 2002-02-14 | 2003-11-27 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
| US7074825B2 (en) * | 2002-03-07 | 2006-07-11 | Huanbiao Mo | Composition and method for treating cancer |
| AU2002950713A0 (en) * | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| US20040067890A1 (en) * | 2002-10-04 | 2004-04-08 | Gupta Shyam K. | Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions |
| US6645514B1 (en) * | 2002-12-19 | 2003-11-11 | Access Business Group International, Llc | Increasing skin cell renewal with water-soluble Vitamin E |
| BRPI0406484A (pt) * | 2003-01-17 | 2005-12-06 | Vital Health Sciences Pty Ltd | Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado |
| US7033998B2 (en) * | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| AU2003901812A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphates of secondary alcohols |
| AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
| AU2003901813A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Pharmaceutical derivatives |
| US7207669B2 (en) * | 2003-12-19 | 2007-04-24 | Arizona Chemical Company | Jet printing inks containing polymerized fatty acid-based polyamides |
| ATE426399T1 (de) * | 2004-02-23 | 2009-04-15 | Euro Celtique Sa | Missbrauchsichere transdermale abgabevorrichtung fur opioide, enthaltend opioidantagonist in form von mikrokugelchen |
| AU2005202477B2 (en) | 2004-03-03 | 2005-12-15 | Vital Health Sciences Pty Ltd | Alkaloid formulations |
| DE602005020638D1 (de) | 2004-06-29 | 2010-05-27 | Japan Science & Tech Agency | Selektives kultivierungsverfahren und trennverfahren für kleine hepatozyten mit verwendung von hyaluronsäure |
| MX2007001356A (es) * | 2004-08-03 | 2007-04-23 | Vital Health Sciences Pty Ltd | Portador para administracion enterica. |
| US20060120979A1 (en) * | 2004-12-02 | 2006-06-08 | Joel Rubin | Skin care composition comprising hydroquinone and a substantially anhydrous base |
| US20090239827A1 (en) | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
| EP1858508A4 (en) | 2005-03-03 | 2009-01-07 | Vital Health Sciences Pty Ltd | COMPOUNDS HAVING ANTICANCER PROPERTIES |
| JP4270212B2 (ja) | 2005-03-29 | 2009-05-27 | セイコーエプソン株式会社 | 基板間隔調整装置、基板間隔調整方法、および液晶表示装置の製造方法 |
| US20060228395A1 (en) * | 2005-04-11 | 2006-10-12 | Robert Lamb | Vitamin E phosphate/phosphatidylcholine liposomes to protect from or ameliorate cell damage |
| CA2611831C (en) * | 2005-06-17 | 2014-09-16 | Vital Health Sciences Pty Ltd. | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| KR100764679B1 (ko) * | 2005-07-22 | 2007-10-09 | 익수제약 주식회사 | 파록세틴을 함유하는 경피투여용 패취제 |
| US7446096B2 (en) * | 2005-12-19 | 2008-11-04 | Industrial Technology Research Institute | Glutathione based delivery system |
| US20090005348A1 (en) * | 2005-12-23 | 2009-01-01 | Vital Health Sciences Pty Ltd | Compounds Having Cytokine Modulating Properties |
| WO2008034178A1 (en) | 2006-09-21 | 2008-03-27 | Salvatore Iemma | Topical depilating composition |
| JP5201858B2 (ja) | 2007-03-26 | 2013-06-05 | 花王株式会社 | 遊離脂肪酸が低減された油脂の製造方法 |
| FR2921259B1 (fr) * | 2007-09-26 | 2015-02-13 | Lvmh Rech | Utilisation cosmetique du phosphate de tocopherol comme agent anti-vieillissement de la peau |
| EP2113242A1 (en) * | 2008-05-02 | 2009-11-04 | Pangaea Laboratories Limited | Antioxidant for use in cosmetic, medicated and pharmaceutical preparations |
| US20090297591A1 (en) | 2008-05-30 | 2009-12-03 | Orient Pharma Co., Ltd. | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds |
| JP5132700B2 (ja) | 2010-02-22 | 2013-01-30 | 三菱電機株式会社 | 手乾燥装置 |
-
2005
- 2005-03-03 AU AU2005202477A patent/AU2005202477B2/en not_active Ceased
- 2005-03-03 DE DE602005025979T patent/DE602005025979D1/de not_active Expired - Lifetime
- 2005-03-03 CA CA2557354A patent/CA2557354C/en not_active Expired - Fee Related
- 2005-03-03 BR BRPI0508125-4A patent/BRPI0508125A/pt not_active IP Right Cessation
- 2005-03-03 JP JP2007501066A patent/JP4847437B2/ja not_active Expired - Fee Related
- 2005-03-03 US US10/551,203 patent/US20060281716A1/en not_active Abandoned
- 2005-03-03 AT AT05706340T patent/ATE495730T1/de not_active IP Right Cessation
- 2005-03-03 RU RU2006131997/15A patent/RU2477136C2/ru not_active IP Right Cessation
- 2005-03-03 EP EP05706340A patent/EP1720551B9/en not_active Expired - Lifetime
- 2005-03-03 DK DK05706340.6T patent/DK1720551T3/da active
- 2005-03-03 WO PCT/AU2005/000307 patent/WO2005084678A1/en not_active Ceased
- 2005-03-03 NZ NZ549567A patent/NZ549567A/en not_active IP Right Cessation
-
2006
- 2006-08-30 IL IL177781A patent/IL177781A/en not_active IP Right Cessation
- 2006-09-01 KR KR1020067017766A patent/KR101173159B1/ko not_active Expired - Fee Related
-
2010
- 2010-01-20 US US12/690,735 patent/US8529947B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL177781A (en) | 2015-03-31 |
| DE602005025979D1 (de) | 2011-03-03 |
| KR101173159B1 (ko) | 2012-08-16 |
| HK1098684A1 (en) | 2007-07-27 |
| RU2477136C2 (ru) | 2013-03-10 |
| WO2005084678A1 (en) | 2005-09-15 |
| BRPI0508125A (pt) | 2007-07-17 |
| US8529947B2 (en) | 2013-09-10 |
| DK1720551T3 (da) | 2011-05-16 |
| CA2557354C (en) | 2013-05-07 |
| EP1720551B1 (en) | 2011-01-19 |
| EP1720551A4 (en) | 2007-04-04 |
| CA2557354A1 (en) | 2005-09-15 |
| ATE495730T1 (de) | 2011-02-15 |
| JP4847437B2 (ja) | 2011-12-28 |
| JP2007526256A (ja) | 2007-09-13 |
| NZ549567A (en) | 2009-10-30 |
| US20060281716A1 (en) | 2006-12-14 |
| KR20060130195A (ko) | 2006-12-18 |
| EP1720551B9 (en) | 2011-09-21 |
| US20100209459A1 (en) | 2010-08-19 |
| AU2005202477B2 (en) | 2005-12-15 |
| EP1720551A1 (en) | 2006-11-15 |
| IL177781A0 (en) | 2006-12-31 |
| AU2005202477A1 (en) | 2005-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006131997A (ru) | Алкалоидные составы | |
| JP2007526256A5 (ru) | ||
| MX2023015533A (es) | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. | |
| MX2025001020A (es) | Compuesto de anillo fusionado, metodo de preparacion del mismo y su aplicacion medicinal | |
| RU2007102034A (ru) | Транспортирующий наполнитель для энтерального применения | |
| JP2005506972A5 (ru) | ||
| US11999736B1 (en) | Pyrazino[2′,1′:2,3]imidazo[4,5-b][1,7]naphthyridines compounds as CK2 inhibitors | |
| CA2448251A1 (en) | Metal complexes and therapeutic uses thereof | |
| TW200517127A (en) | Novel composition | |
| US11952378B1 (en) | Pyrrolo[2,3-c]isoquinoline-1,2-dione compounds as CK2 inhibitors | |
| MX2025001734A (es) | Formas farmacéuticas sólidas orales que contienen cannabinoides | |
| US11891397B1 (en) | Pyrido[4′,3′:4,5]pyrrolo[3,2-c][1,7]naphthyridin-10-one compounds as CK2 inhibitors | |
| US12180209B1 (en) | Pyrrolo[3,2-c][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | |
| US11926629B1 (en) | Pyrido[3′,4′:4,5]pyrrolo[2,3-c]isoquinoline compounds as CK2 inhibitors | |
| US11891394B1 (en) | Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors | |
| US11858935B1 (en) | Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | |
| US11866437B1 (en) | 1,2-dioxo-2,3-dihydro-1H-pyrrolo[2,3-c]quinoline-7-carboxylic acid compounds as CK2 inhibitors | |
| US11884670B1 (en) | Pyrido[4′,3′:4,5]pyrrolo[3,2-c][2,7]naphthyridin-10-one compounds as CK2 inhibitors | |
| US11891377B1 (en) | Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors | |
| CN112521357A (zh) | 一种长效低成瘾性hnk衍生物及其制备方法 | |
| US12024518B1 (en) | Pyrazolo[4,3-C][1,6]naphthyridines as CK2 inhibitors | |
| US12258345B1 (en) | Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors | |
| US12071437B1 (en) | Pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine-2-carboxylic acids as CK2 inhibitors | |
| US12012407B1 (en) | Pyrazolo[1,5-a]pyrido[4,3-e]pyrimidine-3-carboxylic acids as CK2 inhibitors | |
| US12168662B1 (en) | Pyrido[4′,3′:4,5]pyrrolo[2,3-c][2,7]naphthyridines compounds as CK2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20120703 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20120730 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170304 |